Tumors disrupt the structure and function of surrounding normal tissues, creating a wound healing response that is largely governed by local immune cells. This wound-healing response actively shields the tumor from immune detection and attack, fostering tumor survival and growth. Overcoming this immune suppressive microenvironment is key to successful cancer treatment. Odetiglucan binds unique receptors (Dectin, CR3, FcɣR) on these altered immune cells, reprogramming the local tumor environment and enabling tumor detection and destruction.
It’s time we recognize cancer as a chronic disease and focus on developing therapies that address the most common cause of cancer mortality: relapse and metastasis.
Cancers usually start localized within a single tissue and then cells from the primary tumor spread to other organs. So even when primary tumors are surgically removed or seem to have been successfully cleared, treatment-resistant cancer cells have often already disseminated elsewhere in the body and lie dormant, waiting to reawaken as relapse and metastatic disease.
The immunosuppressive tumor microenvironment and adaptive stress biology allow these cells to persist. We believe treatments focused on modulating these foundational barriers will meaningfully impact patient outcomes.